CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) announced today the recent initiation of the Phase 2 clinical trial AFFINITY, designed to evaluate opicinumab as an investigational add-on ...

Nov. 18, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that AFFINITY DUCHENNE ®, the ... positive efficacy and safety data from the Phase I/II portion of the study, including ...

The company also announced new, positive efficacy and safety data from the Phase I/II portion of the study, including the first functional data. Affinity Duchenne data updates: Results include 12 ...

(RTTNews) - Biogen Inc. (BIIB) announced Wednesday the recent initiation of the Phase 2 clinical trial AFFINITY, designed to evaluate opicinumab as an investigational add-on therapy in people with ...

REGENXBIO (RGNX) reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of RGX-202, a differentiated investigational gene therapy ...

(RTTNews) - REGENXBIO Inc. (RGNX) Wednesday reported additional positive results from the Phase I/II AFFINITY DUCHENNE trial of RGX-202 in patients with Duchenne muscular dystrophy. The Phase I/II ...